Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BROADWAY phase 3 trial of obicetrapib in HeFH and/or ASCVD
NL-OMON53507Phase 3Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Jun 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia, familial hypercholesterolemia (FH) and atherosclerotic disease comparing Obicetrapib 10 mg with Placebo (2 arms). Primary endpoint: Percent change from baseline to Day 84 in LDL-C. Started Jun 2022; status: completed.
02
Drugs
obicetrapib
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)atherosclerotic disease
Beyond the preview
Go deeper on NL-OMON53507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53507.